Sensei Biotherapeutics, Inc.
SNSE
$12.63
-$0.37-2.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.49M | 11.33M | 11.37M | 12.24M | 12.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 185.64M | 22.29M | 24.65M | 27.63M | 30.21M |
| Operating Income | -185.64M | -22.29M | -24.65M | -27.63M | -30.21M |
| Income Before Tax | -184.46M | -21.09M | -24.14M | -26.82M | -29.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -184.46 | -21.09 | -24.14 | -26.82 | -29.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.46M | -21.09M | -24.14M | -26.82M | -29.03M |
| EBIT | -185.64M | -22.29M | -24.65M | -27.63M | -30.21M |
| EBITDA | -185.51M | -22.15M | -24.22M | -26.89M | -29.18M |
| EPS Basic | -142.73 | -16.73 | -19.16 | -21.31 | -23.08 |
| Normalized Basic EPS | -89.30 | -10.63 | -11.78 | -13.13 | -14.26 |
| EPS Diluted | -142.73 | -16.73 | -19.16 | -21.31 | -23.08 |
| Normalized Diluted EPS | -89.30 | -10.63 | -11.78 | -13.13 | -14.26 |
| Average Basic Shares Outstanding | 5.08M | 5.04M | 5.04M | 5.04M | 5.03M |
| Average Diluted Shares Outstanding | 5.08M | 5.04M | 5.04M | 5.04M | 5.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |